Online TRT After Dec 31, 2026: The DEA Deadline Explained

This page is about the federal rules as of November 6, 2026. It's not legal advice, state rules can be stricter, and the DEA could act any day. We'll update it when it does.

Testosterone is a Schedule III controlled substance, in the same broad category as some prescription painkillers and anabolic steroids, because of its potential for misuse. Prescribing controlled substances over the internet is governed by the Ryan Haight Act of 2008, which generally requires at least one in-person medical evaluation before a controlled drug is prescribed by telemedicine. After that one evaluation, the federal law doesn't set a repeat or annual exam.

During the pandemic, the DEA and HHS waived the in-person requirement. That waiver has been extended four times. The latest, published at the end of 2025, lets DEA-registered clinicians prescribe Schedule II to V drugs through audio-video telemedicine with no prior in-person visit until December 31, 2026. The DEA called it a "bridge" to permanent rules. Our online-therapy team covers the same rules for ADHD and anxiety medication in telehealth prescribing and the DEA in 2026.

It's the permanent framework meant to replace the temporary waiver. The proposed version, released in January 2025, would create a special DEA registration for clinicians who prescribe Schedule III to V drugs, testosterone included, by telemedicine. As summarized by the American Hospital Association and law firm Bradley, it proposed:

• a separate DEA telemedicine registration for each state where patients are treated;
• prescribing by audio-video visit, with limited exceptions;
• checks of state prescription-monitoring databases before prescribing;
• no special registration needed where the clinician has already seen the patient in person.

The DEA sent its final version to the White House Office of Information and Regulatory Affairs on August 25, 2026. Its text hasn't been made public, and it's unknown how it compares with the 2025 proposal.

It depends on what happens in the next eight weeks. There are three realistic outcomes:

1. The final rule is published. Online clinics register under the new system and keep prescribing by video, under its conditions. Some patients may still need an in-person visit, depending on the final text.
2. Another extension. The waiver is pushed back again, as it has been at every deadline since 2023, and nothing changes for now.
3. The waiver lapses with nothing in place. The Ryan Haight Act's in-person requirement applies again, and clinics would need patients to have an in-person evaluation, typically with the prescribing clinician or through an arrangement the law allows.

In every case, the one thing that protects you is a plan. A good online clinic should be able to tell you today what it will do in each scenario, including whether it can arrange an in-person visit near you.

If you're choosing or switching provider, our three highest-ranked online TRT clinics are below. When you compare them, ask each one how it's preparing for the deadline.

• Ask your clinic directly what its plan is for January 1, 2027, and whether it has a way to arrange an in-person evaluation in your state.
• Keep your labs current. Up-to-date blood work makes any transition, to a new clinic or an in-person doctor, faster.
• Don't stockpile, and don't buy from unlicensed sellers. "Research chemical" or overseas testosterone has no quality control, and stopping or changing your dose abruptly carries its own risks.
• Know your local options. If you'd rather not depend on telehealth rules at all, see our comparison of TRT clinics vs online providers.

Yes. The federal rules set the floor, and states can add their own requirements, such as an in-person exam before a controlled-substance prescription or limits on which clinicians can prescribe by telehealth. Those rules vary and change often, so check with your clinic, which has to follow the rules of the state you're in when you're treated. Our guide to how to get TRT online covers the standard steps.

The FDA has been loosening some of testosterone's label language. In February 2025 it removed the wording about increased cardiovascular risk from the boxed warning, after the large TRAVERSE trial, while adding a class-wide warning that testosterone can raise blood pressure. In June 2026 it asked manufacturers to remove the limitation on use for age-related low testosterone and to revise the safety information on prostate cancer and benign prostatic hyperplasia. Under HHS's proposal, the prostate cancer contraindication would apply only to metastatic disease, and labels would still tell doctors to screen and monitor men, Healio reported. These were requests to manufacturers, so check whether the new labels have been finalized.

An FDA expert panel on testosterone therapy met in December 2025, and some panelists argued testosterone shouldn't be a controlled substance at all. Panel views aren't binding, and testosterone remains Schedule III. For the safety picture as it stands, see is TRT safe? and TRT side effects.

Online TRT isn't guaranteed to end on December 31, 2026, but the rule that makes video-only prescribing possible does expire then, and the permanent replacement still isn't public. The most likely impact, if any, is an in-person evaluation. Ask your clinic for its plan, keep your labs current, and don't stockpile or turn to unlicensed sellers. If low testosterone is new to you, start with how low testosterone is diagnosed. Last checked November 6, 2026. This is general information, not legal or medical advice.